Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

    NCT07274787 · start 2026-12-01

    Registered record
    Registry ID
    NCT07274787
    Conditions
    GBM
    Interventions
    NaviFUS System; Lumason; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-12-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGBM
    InterventionNaviFUS System; Lumason; Bevacizumab
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Upneeq vs. Lumify Ptosis

    NCT07390578 · start 2026-12-01

    Registered record
    Registry ID
    NCT07390578
    Conditions
    Acquired Ptosis
    Interventions
    Oxymetazoline 0.1% (Upneeq); Brimonidine 0.025% (Lumify)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2027-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Ptosis
    InterventionOxymetazoline 0.1% (Upneeq); Brimonidine 0.025% (Lumify)
    PhasePhase 4
    Registry statusNot yet recruiting

  • FLT3-ITD Targeted Therapy in Fit AML Patients

    NCT07425808 · start 2026-12-01

    Registered record
    Registry ID
    NCT07425808
    Conditions
    AML (Acute Myeloid Leukemia)
    Interventions
    Gilteritinib; Venetoclax; Azacitidine (AZA); Local standard of care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2032-02-01
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML (Acute Myeloid Leukemia)
    InterventionGilteritinib; Venetoclax; Azacitidine (AZA); Local standard of care (SOC)
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease

    NCT07718659 · start 2026-12-01

    Registered record
    Registry ID
    NCT07718659
    Conditions
    Parkinson's Disease (PD); Parkinsonian Disorders
    Interventions
    ZR001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2030-12-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD); Parkinsonian Disorders
    InterventionZR001
    PhasePhase 1
    Registry statusNot yet recruiting

  • Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)

    NCT07740512 · start 2026-12-01

    Registered record
    Registry ID
    NCT07740512
    Conditions
    Lysosomal Storage Disorders; Sandhoff Disease; Krabbe Disease; CLN2; CLN3
    Interventions
    PLX-200
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-02-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLysosomal Storage Disorders; Sandhoff Disease; Krabbe Disease; CLN2 +1 more
    InterventionPLX-200
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study

    NCT07751497 · start 2026-12-01

    Registered record
    Registry ID
    NCT07751497
    Conditions
    Vestibular Migraine
    Interventions
    Rimegepant; Flunarizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-04-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVestibular Migraine
    InterventionRimegepant; Flunarizine
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

    NCT07786571 · start 2026-12-01

    Registered record
    Registry ID
    NCT07786571
    Conditions
    Type 2 Diabetes Mellitus (T2DM); Chronic Renal Insufficiency; Chronic Kidney Disease (Stages 3b-5); Glucose Homeostasis
    Interventions
    Dorzagliatin; Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-07-01
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus (T2DM); Chronic Renal Insufficiency; Chronic Kidney Disease (Stages 3b-5); Glucose Homeostasis
    InterventionDorzagliatin; Linagliptin
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi

    NCT07804368 · start 2026-12-01

    Registered record
    Registry ID
    NCT07804368
    Conditions
    Coccidioidomycosis; Blastomycosis; Histoplasmosis; Dimorphic Fungal Infection; Endemic Mycoses
    Interventions
    Oteseconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2028-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoccidioidomycosis; Blastomycosis; Histoplasmosis; Dimorphic Fungal Infection +1 more
    InterventionOteseconazole
    PhasePhase 2
    Registry statusNot yet recruiting

  • Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After Trauma

    NCT07832331 · start 2026-12-01

    Registered record
    Registry ID
    NCT07832331
    Conditions
    Vocal Cord Paralysis; Recurrent Laryngeal Nerve Palsy
    Interventions
    4-Aminopyridine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2027-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVocal Cord Paralysis; Recurrent Laryngeal Nerve Palsy
    Intervention4-Aminopyridine
    PhasePhase 1
    Registry statusNot yet recruiting

  • NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI

    NCT05635851 · start 2026-12

    Registered record
    Registry ID
    NCT05635851
    Conditions
    Spinal Cord Injuries; Autonomic Dysreflexia
    Interventions
    Glyceryl Trinitrate Only Product in Oromucosal Dose Form; Placebo sublingual spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2028-02
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries; Autonomic Dysreflexia
    InterventionGlyceryl Trinitrate Only Product in Oromucosal Dose Form; Placebo sublingual spray
    PhasePhase 2
    Registry statusNot yet recruiting

  • COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer

    NCT06790589 · start 2026-12

    Registered record
    Registry ID
    NCT06790589
    Conditions
    Advanced Differentiated Thyroid Gland Carcinoma
    Interventions
    Levothyroxine Oral Tablet [Synthroid]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2031-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Differentiated Thyroid Gland Carcinoma
    InterventionLevothyroxine Oral Tablet [Synthroid]
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

    NCT07125183 · start 2026-12

    Registered record
    Registry ID
    NCT07125183
    Conditions
    Sarcoma
    Interventions
    Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-12
    Completion
    2029-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionDoxorubicin
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease

    NCT07671222 · start 2026-12

    Registered record
    Registry ID
    NCT07671222
    Conditions
    Sjogren Syndrome; Sjogren Syndrome With Keratoconjunctivitis; Dry Eye Disease (DED)
    Interventions
    Infliximab 0.1%; Loteprednol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2028-03
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSjogren Syndrome; Sjogren Syndrome With Keratoconjunctivitis; Dry Eye Disease (DED)
    InterventionInfliximab 0.1%; Loteprednol
    PhasePhase 2
    Registry statusNot yet recruiting

  • This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse Effects

    NCT07676669 · start 2026-12

    Registered record
    Registry ID
    NCT07676669
    Conditions
    Bipolar 1 Depression
    Interventions
    Lumateperone; Cariprazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2027-08
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar 1 Depression
    InterventionLumateperone; Cariprazine
    PhasePhase 4
    Registry statusNot yet recruiting

  • Enhancing Amoxicillin Pharmacokinetics and Pharmacodynamics Parameters With Probenecid in Bone and Joint Infections

    NCT07764302 · start 2026-12

    Registered record
    Registry ID
    NCT07764302
    Conditions
    Osteoarticular Infections (OAIs)
    Interventions
    Oral probenecid added to oral amoxicillin for osteoarticular infections
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2029-09
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarticular Infections (OAIs)
    InterventionOral probenecid added to oral amoxicillin for osteoarticular infections
    PhasePhase 3
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.